Clinical trials: Cystic Fibrosis Lung Disease
Cystic Fibrosis
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF…
- Trial name
- NCT03447249
- Testing
- VX-659/TEZ/IVA, IVA
- Where
- 101 sites in United States, Australia and 9 more
- Volunteers
- 385 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Vitamin D Deficiency, Cystic Fibrosis
PK/PD of Vitamin D3 in Adults With CF
Despite the extensive literature on adverse clinical outcomes associated with vitamin D deficiency, there are currently no proven treatment strategy that effectively achieves and maintains optimal serum vitamin D status in cystic…
- Trial name
- NCT03734744
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Southern California
Cystic Fibrosis
BioEnergetics and Metabolomics in Cystic Fibrosis
With better medical care, patients with cystic fibrosis (CF), a life-threatening disease, are enjoying longer lives. As the CF life expectancy increases, conditions such as CF-related diabetes (CFRD) become more prevalent.
- Trial name
- BEAM-CF (NCT02225899)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emory University
Cystic Fibrosis
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
This study will evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF…
- Trial name
- NCT03525444
- Testing
- VX-445/TEZ/IVA, IVA
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 405 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis
In this research, we will use established surveys to look at the relationship between various styles of coping with a disease, religious coping styles, treatment compliance, locus of control, broad measures of mental health and…
- Trial name
- NCT00577252
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Akron Children's Hospital
Cystic Fibrosis
Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation in CF
The aim of this study is to develop a reliable and valid instrument to measure symptom management (experience and / or management strategies) during exacerbation episodes in CF patients.
- Trial name
- NCT02464267
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University of Zurich
Cystic Fibrosis
Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.
Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-032 in healthy adult subjects (Phase 1) and of two doses in Adults with Cystic Fibrosis (Phase 1b).
- Trial name
- NCT05712538
- Testing
- ARCT-032
- Where
- New Zealand
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Pancreatic Exocrine Insufficiency
The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The DETECTION Study)
DETECTION. The development of a metabolomic test to diagnose and quantify pancreatic exocrine insufficiency.
- Trial name
- DETECTION (NCT05980221)
- Testing
- Metabolomics, 13C MTGT
- Where
- United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Cystic Fibrosis
Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients
The purpose of this study is to determine which biological marker, or association of biological markers, best predict clinical response of cystic fibrosis patients to CFTR modulators.
- Trial name
- BIO-CFTR (NCT02965326)
- Testing
- Nasal swab; rectal biopsy.
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Hôpital Necker-Enfants Malades
Cystic Fibrosis, Periodontitis
Cystic Fibrosis and Periodontal Diseases
The number of CF adults is increasing year after year (61.7% in 2021) confirming that patients are living longer. These data do not leave aside the desire to see CF patients "age well" considering of all the comorbidities linked…
- Conditions
- Cystic Fibrosis, Periodontitis, Gingivitis
- Trial name
- MucoParo (NCT06133335)
- Testing
- Periodontal examination
- Where
- France
- Volunteers
- 50 people
- Sponsor
- CHU de Reims
Cystic Fibrosis
19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation
The purpose of this study is to use perfluorinated gas imaging to highlight regions of functional variation within the lungs of participants with cystic fibrosis (CF), and to correlate this with changes in spirometry, lung…
- Trial name
- NCT03497117
- Testing
- Lung Clearance Index, MRI with PFP
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of North Carolina, Chapel Hill
Cystic Fibrosis
Zoledronic Acid in Cystic Fibrosis
Null hypotheses: zoledronic acid does not improve bone density in cystic fibrosis. Low bone mineral density (osteoporosis) is prevalent in adults with cystic fibrosis (CF); they have an increased rate of bone fractures in…
- Trial name
- IZAC (NCT01702415)
- Testing
- Zoledronic acid
- Where
- United Kingdom
- Sponsor
- Papworth Hospital NHS Foundation Trust
Cystic Fibrosis
Omega 3 Supplementation in Cystic Fibrosis Patients
Essential fatty acids (EFA) deficiency has been often reported in patients with cystic fibrosis (CF), particularly in those homozygous for the DF508 mutation.
- Trial name
- NCT00959010
- Testing
- omega-3 triglycerides
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Queen Fabiola Children's University Hospital
Cystic Fibrosis, Mucociliary Clearance
A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)
The purpose of this study is to evaluate the safety and tolerability of GS-9411 in patients with Cystic Fibrosis. GS-9411 is a sodium channel inhibitor, that may restore airway hydration and mucociliary clearance in the lung.
- Trial name
- NCT01025713
- Testing
- GS-9411
- Where
- Australia
- Sponsor
- Gilead Sciences
Cystic Fibrosis, Bronchiectasis
Adherence to Airway Clearance. Novel Approaches to Improving Adherence
An airway clearance technique (ACT) is one of the core treatments for children with chronic lung diseases who are unable to clear their secretions effectively.
- Trial name
- NCT02906826
- Testing
- Video game
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Breast Cancer, Breast Neoplasm
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
The accuracy of breast examinations and ultrasonography performed clinically to detect breast mass varies greatly depending on the physician\'s skill level, and the accuracy of breast examinations by non-experts is…
- Conditions
- Breast Cancer, Breast Neoplasm, Artificial Intelligence, Ultrasonography
- Trial name
- NCT06255808
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Cystic Fibrosis
Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study
The purpose of this study is to determine the efficacy and safety of chronic treatment with inhaled dry powder mannitol in subjects with cystic fibrosis.
- Trial name
- NCT00446680
- Testing
- Mannitol
- Where
- 29 sites in Australia, Ireland and 1 more
- Volunteers
- 340 people
- Sponsor
- Syntara
Cystic Fibrosis
COVID-19 Antibody Responses In Cystic Fibrosis
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due…
- Trial name
- CAR-CF (NCT05074680)
- Testing
- Blood sampling
- Where
- 2 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cystic Fibrosis
The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
This study will assess whether rhDNase treatment improves ventilation inhomogeneity as assessed by lung clearance index (LCI) in patients with cystic fibrosis (CF).
- Trial name
- NCT00557089
- Testing
- rhDNAse
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- The Hospital for Sick Children
Cystic Fibrosis
Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients
Safety, tolerability and pharmacokinetics following repeated doses (15-day dosing)
- Trial name
- NCT02269189
- Testing
- BIIL 284 BS, high dose, BIIL 284 BS, low dose
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.